dc.creator | Syriopoulou V., Dailiana Z., Dmitriy N., Utili R., Pathan R., Hamed K. | en |
dc.date.accessioned | 2023-01-31T10:05:06Z | |
dc.date.available | 2023-01-31T10:05:06Z | |
dc.date.issued | 2016 | |
dc.identifier | 10.1097/INF.0000000000001076 | |
dc.identifier.issn | 08913668 | |
dc.identifier.uri | http://hdl.handle.net/11615/79544 | |
dc.description.abstract | Background: This subgroup analysis of the European Cubicin Outcomes Registry Experience evaluated the safety and effectiveness of daptomycin in children and adolescent patients (<18 years). Methods: Clinical outcomes at the end of therapy were assessed as success (cured or improved), failure or nonevaluable. Safety was assessed for up to 30 days post treatment. Results: Eighty-one children and adolescent patients were included in this study. The most common primary infections were bacteremia (19.8%), complicated skin and soft-tissue infection (18.5%), osteomyelitis (13.6%), endocarditis (12.3%), foreign body/prosthetic infection (12.3%), uncomplicated skin and soft-tissue infection (9.9%) and other (13.6%). Daptomycin doses ranged from 4 to >10 mg/kg/day. Median duration of therapy was 12.5 (interquartile range, 7-25; mean, 16.7; standard deviation, 12.8) days. Staphylococcus aureus (46.7%) was the most commonly isolated pathogen (23.8% methicillin-resistant S. aureus). Forty-nine (60.5%) patients completed daptomycin therapy without further antibiotics, 27 (33.3%) switched to another antibiotic, 4 (4.9%) discontinued because of adverse events (AEs) and 1 (1.2%) discontinued because of other reason. Overall, 75 (92.6%; 95% confidence interval: 95.2-100.0%) patients achieved clinical success; 39 of 41 (95.1%) patients receiving daptomycin monotherapy and 36 of 40 (90.0%) patients receiving concomitant antibiotics. Six (7.4%) patients reported AEs, including 1 patient with increased blood creatine phosphokinase. Three (3.7%) patients had serious AEs; 1 (1.2%) had a serious AE possibly related to daptomycin. Conclusion: Daptomycin, alone or combined with other antibiotics and/or surgery, demonstrated high clinical success rates against a wide variety of infections and was well tolerated in children and adolescents. © Copyright 2016 Wolters Kluwer Health, Inc. All rights reserved. | en |
dc.language.iso | en | en |
dc.source | Pediatric Infectious Disease Journal | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84957618408&doi=10.1097%2fINF.0000000000001076&partnerID=40&md5=e455fdcc943cf0855aece40e6c62b1d4 | |
dc.subject | creatine kinase | en |
dc.subject | daptomycin | en |
dc.subject | antiinfective agent | en |
dc.subject | daptomycin | en |
dc.subject | acute kidney failure | en |
dc.subject | adolescent | en |
dc.subject | anaphylaxis | en |
dc.subject | antibiotic therapy | en |
dc.subject | Article | en |
dc.subject | bacteremia | en |
dc.subject | bacterial arthritis | en |
dc.subject | bacterial endocarditis | en |
dc.subject | bacterium isolation | en |
dc.subject | child | en |
dc.subject | coagulase negative Staphylococcus | en |
dc.subject | controlled study | en |
dc.subject | creatine kinase blood level | en |
dc.subject | debridement | en |
dc.subject | device removal | en |
dc.subject | drug efficacy | en |
dc.subject | drug safety | en |
dc.subject | drug substitution | en |
dc.subject | drug withdrawal | en |
dc.subject | dyspnea | en |
dc.subject | Enterococcus faecium | en |
dc.subject | female | en |
dc.subject | follow up | en |
dc.subject | Gram positive infection | en |
dc.subject | heart valve replacement | en |
dc.subject | human | en |
dc.subject | hypersensitivity | en |
dc.subject | incision | en |
dc.subject | lung hemorrhage | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | methicillin resistant Staphylococcus aureus | en |
dc.subject | monotherapy | en |
dc.subject | osteomyelitis | en |
dc.subject | osteosarcoma | en |
dc.subject | outcome assessment | en |
dc.subject | preschool child | en |
dc.subject | priority journal | en |
dc.subject | prosthesis infection | en |
dc.subject | rash | en |
dc.subject | school child | en |
dc.subject | side effect | en |
dc.subject | skin infection | en |
dc.subject | soft tissue infection | en |
dc.subject | Staphylococcus aureus | en |
dc.subject | Staphylococcus epidermidis | en |
dc.subject | surgical drainage | en |
dc.subject | tachycardia | en |
dc.subject | treatment duration | en |
dc.subject | urinary tract infection | en |
dc.subject | Drug-Related Side Effects and Adverse Reactions | en |
dc.subject | Gram-Positive Bacterial Infections | en |
dc.subject | infant | en |
dc.subject | newborn | en |
dc.subject | pathology | en |
dc.subject | treatment outcome | en |
dc.subject | Adolescent | en |
dc.subject | Anti-Bacterial Agents | en |
dc.subject | Child | en |
dc.subject | Child, Preschool | en |
dc.subject | Daptomycin | en |
dc.subject | Drug-Related Side Effects and Adverse Reactions | en |
dc.subject | Female | en |
dc.subject | Gram-Positive Bacterial Infections | en |
dc.subject | Humans | en |
dc.subject | Infant | en |
dc.subject | Infant, Newborn | en |
dc.subject | Male | en |
dc.subject | Treatment Outcome | en |
dc.subject | Lippincott Williams and Wilkins | en |
dc.title | Clinical Experience with Daptomycin for the Treatment of Gram-positive Infections in Children and Adolescents | en |
dc.type | journalArticle | en |